Abstract
Chromophobe renal cell carcinoma (chRCC), the third most common histological subtype of RCC, comprises 5–7% of all RCC cases. The aim of the present study was to identify potential biomarkers for chRCC and to examine the underlying mechanisms. A total of 4 profile datasets were downloaded from the Gene Expression Omnibus database to identify differentially expressed genes (DEGs). Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses of DEGs were performed with the Database for Annotation, Visualization and Integrated Discovery. A protein-protein interaction (PPI) network was constructed to predict hub genes. Hub gene expression within chRCC across multiple datasets, as well as overall survival, were investigated by utilizing the Oncomine platform and UALCAN dataset, separately. A total of 266 DEGs (88 upregulated genes and 168 downregulated genes) were identified from 4 profile datasets. Integrating the results from the PPI network, Oncomine platform and survival analysis, CFTR was screened as a key factor in the prognosis of chRCC. GO and KEGG analysis revealed that 266 DEGs were mainly enriched in 17 terms and 9 pathways. The present study identified key genes and potential molecular mechanisms underlying the development of chRCC, and CFTR may be a potential prognostic biomarker and novel therapeutic target for chRCC.
Highlights
Renal cell carcinoma (RCC) is globally the most prevalent cancer affecting the kidney in adults [1]
The results demonstrated that, for cellular component (CC), differentially expressed genes (DEGs) of Chromophobe renal cell carcinoma (chRCC) were mainly enriched in 10 terms, including ‘extracellular exosome’, ‘plasma membrane’, ‘extracellular region’ and ‘extracellular matrix’
ChRCC is the third most common histological subtype of RCC, behind clear cell RCC and papillary RCC [3]; it accounts for 5‐7% of all RCC cases [4]
Summary
Renal cell carcinoma (RCC) is globally the most prevalent cancer affecting the kidney in adults [1]. Chromophobe RCC (chRCC) is the third most common histological subtype of RCC [3], comprising 5‐7% of all RCC cases [4]. Due to advances in technology for the diagnosis and treatment of chRCC, the 5‐year survival rate of chRCC is >75% [5] and the outcome is typically favorable when compared with that of other subtypes [6]. Patients with this disease still have a 5‐10% probability of eventually developing progression and metastasis [7]. It is essential to identify tumor‐specific biomarkers and the underlying molecular mechanisms of chRCC, which may be conducive to improved risk assessment of the disease, guiding clinical decision‐making, and developing novel diagnostic and therapeutic strategies for chRCC
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
